홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

릴루졸레

Riluzole

HCID 5070
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
1744-22-5
표준 SMILES
Nc1nc2ccc(OC(F)(F)F)cc2s1
InChIKey
FTALBRSUTCGOEG-UHFFFAOYSA-N
분자식
C8H5F3N2OS
평균 분자량
234.2 g/mol
단동위원소 질량
234.00746845

개요

Riluzole is a member of benzothiazoles.

이름 및 식별자

우선 이름
Riluzole
IUPAC
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
현지명
릴루졸레
영어명
Riluzole
분자식
C8H5F3N2OS
분자량
234.2

이름 및 동의어

riluzole1744-22-5Rilutek2-Amino-6-(trifluoromethoxy)benzothiazole6-(trifluoromethoxy)-1,3-benzothiazol-2-amineRiluzolRiluzolumRP-542742-Benzothiazolamine, 6-(trifluoromethoxy)-Tiglutik2-amino-6-trifluoromethoxybenzothiazoleRP 54274
이름 더 보기
릴루졸레6-(Trifluoromethoxy)benzo[d]thiazol-2-amineCBI-BB ZERO/0017856-trifluoromethoxy-2-aminobenzothiazole6-TRIFLUOROMETHOXYBENZOTHIAZOLE-2-YL-AMINEuzoLBF-37NSC8463PK 26124
EXSERVANNSC-753433NSC-7598237LJ087RS6FBENZOTHIAZOLE, 2-AMINO-6-TRIFLUOROMETHOXY-BHV-0223PK26124RP54274

데이터베이스 식별자

CAS
1744-22-5
PubChem CID
5070
DTXSID
DTXSID3045192
ChEMBL
CHEMBL744
ChEBI
CHEBI:8863
UNII
7LJ087RS6F
EC Number
605-724-6
Nikkaji
J22.921K

물성

구조 계산 물성

XLogP
3.6
극성 표면적
76.4 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
7
회전 가능 결합 수
1
무거운 원자 수
15
형식 전하
0
복잡도
238

실험 및 물리화학적 성질

Drugs · 3건

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

Pharmaceuticals -> Nervous system -> Other nervous system drugs

LogP · 2건

2.3

3.34

Solubility · 2건

3.95e-02 g/L

22.1 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 5건

Breast Feeding; Lactation; Excitatory Amino Acid Antagonists; Neuroprotective Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Melting Point119 °C
Physical DescriptionSolid

물리화학적 성질

녹는점
116 · 116-118°C
끓는 점
296.3 · 296.3±50.0 °C(Predicted)
밀도
1.572 · 1.572±0.06 g/cm3(Predicted)
저장 조건
2 · 2-8°C
용해도

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H301 (91.9%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 74 reports by companies from 6 notifications to the ECHA C&L Inventory.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 3 (91.9%)

독성 정보

TreatmentTreatment should be supportive and directed toward alleviating symptoms. Severe methemoglobinemia may be rapidly reversible after treatment with methylene blue. (L1712)
Health EffectsMay cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.
Hepatotoxicity · 1건

Serum aminotransferase elevations occur in approximately up to 12% of patients on long term riluzole therapy, but elevations above 3 times the upper limit of normal (ULN) occur in less than 3% of patients. These elevations are usually mild-to-moderate in severity and are rarely associated with symptoms. Most elevations resolve spontaneously, but persistent or marked elevations require drug discontinuation or dose modification. Routine monitoring of serum aminotransferase levels is recommended for the first 6 months of therapy. Clinically apparent liver injury due to riluzole is rare, but several cases have been reported, arising after 1 to 12 months of therapy and characterized by a hepatocellular or mixed pattern of serum enzyme elevations. Immunoallergic and autoimmune features were uncommon. Most cases were mild to moderate in severity and recovery was rapid upon drug discontinuation, but evidently fatal cases have been reported to the sponsor.

화학 및 산업

약리 정보

ATC Code · 3건

N07XX02

N - Nervous system

QN - Nervous system

Protein Binding96% bound to plasma proteins, mainly to albumin and lipoprotein over the clinical concentration range.
Pharmacodynamics · 1건

Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). Riluzole extends survival and/or time to tracheostomy. It is also neuroprotective in various <i>in vivo</i> experimental models of neuronal injury involving excitotoxic mechanisms. The etiology and pathogenesis of amyotrophic lateral sclerosis (ALS) are not known, although a number of hypotheses have been advanced. One hypothesis is that motor neurons, made vulnerable through either genetic predisposition or environmental factors, are injured by glutamate. In some cases of familial ALS the enzyme superoxide dismutase has been found to be defective.

Mechanism of Action · 1건

The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.

Biological Half-LifeThe mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.
Metabolism/Metabolites · 3건

Riluzole is extensively metabolized to six major and a number of minor metabolites, which have not all been identified to date. Metabolism is mostly hepatic, consisting of cytochrome P450&ndash;dependent hydroxylation and glucuronidation. CYP1A2 is the primary isozyme involved in N-hydroxylation; CYP2D6, CYP2C19, CYP3A4, and CYP2E1 are considered unlikely to contribute significantly to riluzole metabolism in humans.

Riluzole has known human metabolites that include N-Hydroxyriluzole, 7-hydroxy-riluzole, 4-hydroxy-riluzole, and 5-hydroxy-riluzole.

관련 반응

68건
반응 기록 만들기
HRID 9568 반응식
HRID 9568반응물로
HRID 30883 반응식
HRID 30883반응물로
HRID 118455 반응식
HRID 118455반응물로
HRID 177030 반응식
HRID 177030반응물로
HRID 205169 반응식
HRID 205169반응물로
HRID 256821 반응식
HRID 256821반응물로
HRID 256824 반응식
HRID 256824반응물로
HRID 410718 반응식
HRID 410718반응물로
이전1 / 9 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
25 mg/mL · DMSO: 25mg/mL
물리적 상태
고체
산도 계수 (pKa)
2.96 · 2.96±0.10(Predicted)
색상
하얀색
Merck
14 · 14,8223
안정성
1 · 제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO 또는 에탄올 용액은 -20°C에서 최대 2개월 동안 보관할 수 있습니다.
InChI
InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
InChIKey
FTALBRSUTCGOEG-UHFFFAOYSA-N
SMILES
S1C2=CC(OC(F)(F)F)=CC=C2N=C1N

화학적 성질

White Crystalline Solid

Exposure RoutesRiluzole is well-absorbed (approximately 90%), with average absolute oral bioavailability of about 60% (CV=30%). A high fat meal decreases absorption, reducing AUC by about 20% and peak blood levels by about 45%.
Toxicity Summary · 1건

The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.

Signs and SymptomsSymptoms include such as nausea and fatigue [Wikipedia].
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Riluzole

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 85 mg/kg (p.o., mice) (L1859) LD50: 34.5 mg/kg (i.v, mice) (L1859) LD50: 45 mg/kg (p.o., rat) (L1859) LD50: 21 mg/kg (i.v, mice) (L1859)

안전 데이터

wgk
3
rtecs
DL2830000
ridadr
UN 2811 6.1/PG 3
독성
LD50 in mice (mg/kg): 46 i.p.; 67 orally (Mizoule)
HS 번호
2934200090
risk_code
25
hazard_code
T,Xi
safety_code
45
포장분류
II
위험 등급
6.1
위험 참고 사항
Irritant
Hazard Classifications
Acute Tox. 2 Oral
스토리지 클래스
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials

Riluzole is extensively metabolized to six major and a number of minor metabolites, which have not all been identified to date. Metabolism is mostly hepatic, consisting of cytochrome P450&ndash;dependent hydroxylation and glucuronidation. CYP1A2 is the primary isozyme involved in N-hydroxylation; CYP2D6, CYP2C19, CYP3A4, and CYP2E1 are considered unlikely to contribute significantly to riluzole metabolism in humans. Half Life: The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.

FDA Pharmacological Classification · 6건

7LJ087RS6F

RILUZOLE

Established Pharmacologic Class [EPC] - Benzothiazole

Chemical Structure [CS] - Benzothiazoles

Riluzole is a Benzothiazole.

RILUZOLE

MeSH Pharmacological Classification · 3건

Drugs used to prevent SEIZURES or reduce their severity.

Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists.

Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.

Absorption, Distribution and ExcretionRiluzole is well-absorbed (approximately 90%), with average absolute oral bioavailability of about 60% (CV=30%). A high fat meal decreases absorption, reducing AUC by about 20% and peak blood levels by about 45%.
Cellular LocationsMembrane

용도 및 제조

Uses · 2건

Use (kg; approx.) in Germany (2009): >100

For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

응용 분야 · 2건

개요Rilutek was launched in Germany, the UK and US (orphan drug status) for treatment of amyotrophic lateral sclerosis (ALS) and is the first drug approved for this indication. A one step synthesis from 4-(trifluoromethoxy)aniline provides a supply of the compound. The source of its neuroprotective and anticonvulsant activity is not clearly understood. It antagonizes excitatory amino acids and blocks presynaptic release of glutamate, is an antagonist of NMDA-induced acetylcholine release and inhibited glutamate and quisqualate induced increases in cGMP but does not bind to NMDA or Kainic receptors. Rilutek has no affinity for glutamate, GABAbenzodiazepine, glycine and adenosine receptors. It easily crosses the blood brain barrier and depresses glutamatergic neurotransmission, stabilizes voltagedependent Na channels in their inactive form and activates G-protein dependent processes.

용도Labeled Riluzole, intended for use as an internal standard for the quantification of Riluzole by GC- or LC-mass spectrometry.

상·하류 제품 정보

상류 원료

트리메톡시-4아닐린